The goal of this clinical trial is to estimate the rate (probability) of complete remission or complete remission with incomplete count recovery (CR/CRi) with negative MRD after induction I and II, event-free survival (EFS), and cumulative incidence (probability) of relapse (CIR), in patients receiving molecular/precision medicine and MRD-driven remission inductions, and to assess secondarily if there is an improvement over the AML2018 protocol.
1、Newly diagnosed, untreated AML；
2、Under 18 years old;
3、Patients who have used hydroxyurea or cytarabine before diagnosis, but the dosage of cytarabine does not exceed 5 days, and the total dose does not exceed 500 mg/m2 (50 mg/m2, q12h × 5d)；
4、 Liver function：Tbil≤2×ULN, ALT/AST≤3×ULN, creatinine clearance ≥50ml/min；Cardiac NYHA grading<3；SaO2>92%;
1、Acute megakaryocytic leukemia (AMKL)；
2、Acute promyelocytic leukemia (APL);
3、Treatment-related secondary AML and AML with definite MDS transformation；
4、Myeloproliferative neoplasm (such as Juvenile myelomonocytic leukemia, JMML);